Title |
Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice
|
---|---|
Published in |
Acta Neuropathologica Communications, July 2015
|
DOI | 10.1186/s40478-015-0217-z |
Pubmed ID | |
Authors |
Karthikeyan Balakrishnan, Ajeet Rijal Upadhaya, Julia Steinmetz, Julia Reichwald, Dorothee Abramowski, Marcus Fändrich, Sathish Kumar, Haruyasu Yamaguchi, Jochen Walter, Matthias Staufenbiel, Dietmar Rudolf Thal |
Abstract |
The deposition of the amyloid β protein (Aβ) in the brain is a hallmark of Alzheimer's disease (AD). Removal of Aβ by Aβ-antibody treatment has been developed as a potential treatment strategy against AD. First clinical trials showed neither a stop nor a reduction of disease progression. Recently, we have shown that the formation of soluble and insoluble Aβ aggregates in the human brain follows a hierarchical sequence of three biochemical maturation stages (B-Aβ stages). To test the impact of the B-Aβ stage on Aβ immunotherapy, we treated transgenic mice expressing human amyloid precursor protein (APP) carrying the Swedish mutation (KM670/671NL; APP23) with the Aβ-antibody β1 or phosphate-buffered saline (PBS) beginning 1) at 3 months, before the onset of dendrite degeneration and plaque deposition, and 2) at 7 months, after the start of Aβ plaque deposition and dendrite degeneration. At 5 months of age, first Aβ aggregates in APP23 brain consisted of non-modified Aβ (representing B-Aβ stage 1) whereas mature Aβ-aggregates containing N-terminal truncated, pyroglutamate-modified AβN3pE and phosphorylated Aβ (representing B-Aβ stage 3) were found at 11 months of age in both β1- and PBS-treated animals. Protective effects on commissural neurons with highly ramified dendritic trees were observed only in 3-month-old β1-treated animals sacrificed at 5 months. When treatment started at 7 months of age, no differences in the numbers of healthy commissural neurons were observed between β1- and PBS-treated APP23 mice sacrificed with 11 months. Aβ antibody treatment was capable of protecting neurons from dendritic degeneration as long as Aβ aggregation was absent or represented B-Aβ stage 1 but had no protective or curative effect in later stages with mature Aβ aggregates (B-Aβ stage 3). These data indicate that the maturation stage of Aβ aggregates has impact on potential treatment effects in APP23 mice. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 23% |
Student > Bachelor | 7 | 23% |
Student > Master | 4 | 13% |
Other | 3 | 10% |
Student > Ph. D. Student | 3 | 10% |
Other | 1 | 3% |
Unknown | 6 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 7 | 23% |
Biochemistry, Genetics and Molecular Biology | 5 | 16% |
Agricultural and Biological Sciences | 4 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Medicine and Dentistry | 2 | 6% |
Other | 4 | 13% |
Unknown | 7 | 23% |